Skip to content

Press Releases

Aug 03, 2020
Esperion to Report Second Quarter 2020 Financial Results August 10, 2020
ANN ARBOR, Mich., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2020 financial results after the close of the U.S. financial markets on August 10, 2020. Following the release, company management will host a webcast and conference call at
Jul 01, 2020
Esperion Announces Publication in the Journal of the American Medical Association Cardiology of Pooled Efficacy Analysis from the Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL® (bempedoic acid) Tablets
ANN ARBOR, Mich., July 01, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled efficacy analysis from the four Phase 3 clinical studies of NEXLETOL, an oral, once-daily LDL-cholesterol lowering medicine, was published in the Journal of the American Medical Association
Jun 22, 2020
Esperion and Daiichi Sankyo Europe Announce Amendment to License and Commercial Collaboration Agreement
Esperion to Receive $150 Million Milestone Payment in June  Esperion Completes Transfer of Marketing Authorization Approvals (MAAs) for NILEMDO™ (bempedoic acid) and NUSTENDI™ (bempedoic acid and ezetimibe) Tablets to DSE      DSE to Initiate Commercial Rollout of NILEMDO and NUSTENDI in Europe
Jun 14, 2020
Esperion Announces Pooled Analysis from Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL™ (Bempedoic Acid) Tablets Presented at the American Diabetes Association 80th Scientific Sessions
ANN ARBOR, Mich., June 14, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled analysis from four Phase 3 clinical studies of NEXLETOL were presented at the American Diabetes Association 80 th Scientific Sessions.  According to the American Diabetes Association (ADA)
Jun 12, 2020
Esperion Confirms NEXLETOL™ (bempedoic acid) Tablets to be Included in Assessment of Non-statin Medicines for Hypercholesterolemia by ICER
ANN ARBOR, Mich., June 12, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today confirms it has received notice that the Institute of Clinical and Economic Review (ICER) plans to assess new non-statin medicines for hypercholesterolemia in the U.S., including the clinical cost effectiveness and
Jun 08, 2020
Esperion to Participate in Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference
ANN ARBOR, Mich., June 08, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on Thursday, June 11, 2020, at 4:40
Jun 04, 2020
Esperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering
– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering – –  Esperion Aims to Set New Industry Standard by Pricing NEXLIZET for Patient Affordability and Access with Minimal to No Paperwork Requirements for Health Care Providers – – Launch Date Accelerated by One
May 27, 2020
Esperion to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference 2020
ANN ARBOR, Mich., May 27, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the Jefferies Virtual Global Healthcare Conference 2020 on Tuesday, June 2, 2020, at 1:30 p.m.
May 15, 2020
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., May 15, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on May 15, 2020, the Compensation Committee of Esperion’s Board of Directors granted 88,902 restricted stock units (RSUs) to 194 new colleagues under Esperion’s 2017 Inducement Equity Incentive Plan.
May 07, 2020
Esperion to Participate in Fireside Chat at the BofA Securities 2020 Healthcare Conference
ANN ARBOR, Mich., May 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the BofA Securities 2020 Healthcare Conference on Tuesday, May 12, 2020, at 9:00 a.m.